JP2024529763A - 6-(シクロプロパンカルボキサミド)-4-((2-メトキシ-3-(1-メチル-1h-1,2,4-トリアゾール-3-イル)フェニル)アミノ)-n-(メチル-d3)ピリダジン-3-カルボキサミドの結晶体 - Google Patents

6-(シクロプロパンカルボキサミド)-4-((2-メトキシ-3-(1-メチル-1h-1,2,4-トリアゾール-3-イル)フェニル)アミノ)-n-(メチル-d3)ピリダジン-3-カルボキサミドの結晶体 Download PDF

Info

Publication number
JP2024529763A
JP2024529763A JP2024510406A JP2024510406A JP2024529763A JP 2024529763 A JP2024529763 A JP 2024529763A JP 2024510406 A JP2024510406 A JP 2024510406A JP 2024510406 A JP2024510406 A JP 2024510406A JP 2024529763 A JP2024529763 A JP 2024529763A
Authority
JP
Japan
Prior art keywords
crystalline form
pxrd
pattern
methyl
room temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024510406A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529763A5 (cg-RX-API-DMAC10.html
Inventor
ウェイ,チェンコウ
シャトック-ゴードン,タニース
オーランド,ジョシュア
ウィリフォード,タビサ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2024529763A publication Critical patent/JP2024529763A/ja
Publication of JP2024529763A5 publication Critical patent/JP2024529763A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024510406A 2021-08-20 2022-08-19 6-(シクロプロパンカルボキサミド)-4-((2-メトキシ-3-(1-メチル-1h-1,2,4-トリアゾール-3-イル)フェニル)アミノ)-n-(メチル-d3)ピリダジン-3-カルボキサミドの結晶体 Pending JP2024529763A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163235635P 2021-08-20 2021-08-20
US63/235,635 2021-08-20
PCT/US2022/040884 WO2023023322A1 (en) 2021-08-20 2022-08-19 Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide

Publications (2)

Publication Number Publication Date
JP2024529763A true JP2024529763A (ja) 2024-08-08
JP2024529763A5 JP2024529763A5 (cg-RX-API-DMAC10.html) 2025-08-26

Family

ID=83283223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024510406A Pending JP2024529763A (ja) 2021-08-20 2022-08-19 6-(シクロプロパンカルボキサミド)-4-((2-メトキシ-3-(1-メチル-1h-1,2,4-トリアゾール-3-イル)フェニル)アミノ)-n-(メチル-d3)ピリダジン-3-カルボキサミドの結晶体

Country Status (7)

Country Link
US (1) US20240368130A1 (cg-RX-API-DMAC10.html)
EP (1) EP4387968B1 (cg-RX-API-DMAC10.html)
JP (1) JP2024529763A (cg-RX-API-DMAC10.html)
KR (1) KR20240050380A (cg-RX-API-DMAC10.html)
CN (1) CN118119614A (cg-RX-API-DMAC10.html)
ES (1) ES3062193T3 (cg-RX-API-DMAC10.html)
WO (1) WO2023023322A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024241347A1 (en) * 2023-05-25 2024-11-28 Msn Laboratories Private Limited, R&D Center Novel polymorphs of 6-(cyclopropanecarbonylamido)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-n-(trideuteriomethyl)pyridazine-3-carboxamide
ES3059443A1 (es) * 2024-09-17 2026-03-20 Moehs Iberica Sl Forma solida de 6-(ciclopropanocarboxamido)-4-((2-metoxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)piridazine-3-carboxilato de metilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de deucravacitinib

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019232138A1 (en) * 2018-05-31 2019-12-05 Bristol-Myers Squibb Company Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
JP2020512380A (ja) * 2017-03-30 2020-04-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 6−(シクロプロパンカルボキサミド)−4−((2−メトキシ−3−(1−メチル−1H−1,2,4−トリアゾール−3−イル)フェニル)アミノ)−N−(メチル−d3)ピリダジン−3−カルボキサミドの結晶形態
WO2020251911A1 (en) * 2019-06-12 2020-12-17 Bristol-Myers Squibb Company Crystalline salt forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220766T1 (hr) * 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
AU2022214313A1 (en) * 2021-01-29 2023-08-17 Bristol-Myers Squibb Company Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
CN117377667A (zh) * 2021-03-29 2024-01-09 百时美施贵宝公司 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020512380A (ja) * 2017-03-30 2020-04-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 6−(シクロプロパンカルボキサミド)−4−((2−メトキシ−3−(1−メチル−1H−1,2,4−トリアゾール−3−イル)フェニル)アミノ)−N−(メチル−d3)ピリダジン−3−カルボキサミドの結晶形態
WO2019232138A1 (en) * 2018-05-31 2019-12-05 Bristol-Myers Squibb Company Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
WO2020251911A1 (en) * 2019-06-12 2020-12-17 Bristol-Myers Squibb Company Crystalline salt forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C.G.WERMUTH編, 最新 創薬化学 下巻, JPN6014029314, 1999, pages 347 - 365, ISSN: 0005886040 *
厚生省医薬安全局審査管理課長: "医薬品の残留溶媒ガイドラインについて", 医薬審, JPN6014031669, 1998, ISSN: 0005886038 *
平山 令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005886037 *
芦澤一英, 医薬品の多形現象と晶析の化学, JPN6015027444, 2002, pages 273 - 278, ISSN: 0005886039 *

Also Published As

Publication number Publication date
ES3062193T3 (en) 2026-04-09
CN118119614A (zh) 2024-05-31
KR20240050380A (ko) 2024-04-18
EP4387968B1 (en) 2025-11-12
WO2023023322A1 (en) 2023-02-23
US20240368130A1 (en) 2024-11-07
EP4387968A1 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
US12545665B2 (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
US11613529B2 (en) Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-D3) pyridazine-3-carboxamide
US12129245B2 (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3) pyridazine-3-carboxamide
US20240190845A1 (en) Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
EP4387968B1 (en) Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
WO2025106462A1 (en) 2-(4-(2-(7, 8-dimethyl-[1,2,4]triazolo[1,5-a] pyridin-6-yl)-3-isopropyl-1h-indol-5-yl)piperidin-1-yl)acetamide salt and crystalline forms thereof
EA044397B1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-(ЦИКЛОПРОПАНКАРБОКСАМИДО)-4-((2-МЕТОКСИ-3-(1-МЕТИЛ-1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ФЕНИЛ)АМИНО)-N-(МЕТИЛ-d3)ПИРИДАЗИН-3-КАРБОКСАМИДА

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260616